Evaluation of Mycobacterium smegmatis as a possible surrogate screen for selecting molecules active against multi-drug resistant Mycobacterium tuberculosis

The Journal of General and Applied Microbiology
Vinita ChaturvediSudhir Sinha

Abstract

New and better drugs are needed for tuberculosis (TB), particularly for the multi-drug resistant (MDR) disease. However, the highly infectious nature of MDR Mycobacterium tuberculosis restricts its use for large scale screening of probable drug candidates. We have evaluated the potential of a screen based on a 'fast grower' mycobacterium to shortlist compounds which could be active against MDR M. tuberculosis. Sensitivity profiles of M. smegmatis, M. phlei and M. fortuitum as well as MDR clinical isolates of M. tuberculosis were determined against anti-TB drugs isoniazid and rifampicin. Among the three fast growers, M. smegmatis was found to display a profile similar to MDR M. tuberculosis. Subsequently we evaluated the performance of M. smegmatis as a 'surrogate' screen for 120 compounds which were synthesized for anti-TB activity. Fifty of these molecules were active against M. tuberculosis H(37)Rv at a minimum inhibitory concentration (MIC) cutoff of <or=12.50 microg/ml. The M. smegmatis based screen showed 100% specificity and 78% sensitivity vis-à-vis MDR M. tuberculosis. These results highlight the utility of M. smegmatis as a primary screen to shortlist compounds for advanced screening against MDR M. tuberculosis.

References

Apr 1, 1978·Journal of Medicinal Chemistry·K C MurdockS A Lang
Jul 1, 1988·The Journal of Infectious Diseases·R J WallaceV A Silcox
Oct 1, 1994·Molecular Microbiology·J Trias, R Benz
Oct 1, 1995·Antimicrobial Agents and Chemotherapy·G A ChungK Duncan
Mar 19, 1999·Biochemical and Biophysical Research Communications·B S ChoudhuriP Chakrabarti
Feb 8, 2000·The Journal of Antimicrobial Chemotherapy·L J PiddockV Ricci
Oct 2, 2002·Journal of Clinical Microbiology·Stefan Panaiotov, Todor Kantardjiev
Jan 24, 2003·International Journal of Epidemiology·Tony Blakely, Clare Salmond
May 14, 2003·Archives of Internal Medicine·Elizabeth L CorbettChristopher Dye
May 22, 2003·Tuberculosis·Marcos A Espinal
Nov 14, 2003·The Journal of Antimicrobial Chemotherapy·Tao Lu, Karl Drlica
Jun 25, 2004·Antimicrobial Agents and Chemotherapy·Xian-Zhi LiHiroshi Nikaido
Mar 23, 2005·Proceedings of the National Academy of Sciences of the United States of America·J Perren CobbUNKNOWN Inflammation and Host Response to Injury Large-Scale Collaborative Research Program
Apr 5, 2005·European Journal of Medicinal Chemistry·D KatiyarR P Tripathi

❮ Previous
Next ❯

Citations

Feb 2, 2011·Assay and Drug Development Technologies·Deborah MaiAdrie J C Steyn
Mar 9, 2012·The Journal of Antimicrobial Chemotherapy·Antima Gupta, Sanjib Bhakta
Mar 19, 2013·Applied and Environmental Microbiology·Victoria L TkachukKim H Ominski
Apr 6, 2012·PloS One·Veeraraghavan UshaGurdyal S Besra
Sep 2, 2011·Future Medicinal Chemistry·Takushi KanekoKhisimuzi Mdluli
Dec 1, 2010·Letters in Applied Microbiology·V K GuptaR L Thakur
Sep 22, 2016·International Journal of Mycobacteriology·Joseph Mwanzia NgutaPhyllis G A Addo
Aug 22, 2015·PloS One·Brilliant B LuthuliFrederick K Balagaddé
May 15, 2004·Medical Hypotheses·Lawrence Broxmeyer
Nov 10, 2015·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·Marta J FiołkaJerzy Wydrych
Apr 8, 2017·Pharmaceutical Biology·Vivek Kumar GuptaAnupam Kaushik
Mar 23, 2019·Health Care for Women International·Benissa E SalemAdeline M Nyamathi
Apr 2, 2020·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Martin JuhásJan Zitko
Nov 22, 2015·The Journal of Biological Chemistry·Deepti SethiKanak L Dikshit
Feb 24, 2017·BMC Complementary and Alternative Medicine·Tafadzwa NyambuyaStanley Mukanganyama
Nov 16, 2016·Assay and Drug Development Technologies·Sofia Santos CostaIsabel Couto
Sep 26, 2019·Frontiers in Pharmacology·Sylvin Benjamin AtebaDieudonné Njamen
Aug 6, 2019·Biochemical and Biophysical Research Communications·Hye-Young SagongKyung-Jin Kim
Apr 3, 2020·Journal of Pharmaceutical Sciences·Priyanka S JahagirdarPadma V Devarajan
May 19, 2021·Tuberculosis·Maria Gabriella S SidrônioValnês S Rodrigues-Junior
Nov 7, 2014·Langmuir : the ACS Journal of Surfaces and Colloids·Priyanka PadwalSarika Mehra
Feb 1, 2018·Chemical Reviews·Tianao Yuan, Nicole S Sampson
Sep 18, 2021·ACS Medicinal Chemistry Letters·R Madison Green, Kevin L Bicker

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antitubercular Agents (ASM)

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antitubercular Agents

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.